Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans

Cardiology (Switzerland)

Volumn 131, Issue 4, 2015, Pages 228-235

  Kim, Eun Hee ^a   Lee, Jung Bok ^a   Kim, Seon Ha ^a   Jo, Min Woo ^a   Hwang, Jenie Yoonoo ^a   Bae, Sung Jin ^a   Jung, Chang Hee ^a   Lee, Woo Je ^a   Park, Joong Yeol ^a   Park, Gyung Min ^b   Kim, Young Hak ^a   Kim, Hong Kyu ^a   Choe, Jaewon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

Author keywords

Cardiovascular disease; Ischemic heart disease; Triglyceride

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DEATH CERTIFICATE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ICD-10; ISCHEMIC HEART DISEASE; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; MIDDLE AGED; ODDS RATIO; RISK FACTOR; SOUTH KOREA;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; ODDS RATIO; REPUBLIC OF KOREA; RISK FACTORS; TRIGLYCERIDES;

EID: 84929675228     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000380941     Document Type: Article

References (35)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
2. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Circulation 2004;110:227-239.
4. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P: The residual risk reduction initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K.
5. Reiner Z: Managing the residual cardiovascular disease risk associated with hdl-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutr Metab Cardiovasc Dis 2013;23:799-807.
6. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123: 2292-2333.
7. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-1036.
8. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
9. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-2152.
10. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-458.
11. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.
12. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724-730.
13. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi Y: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001; 153: 490-499.
14. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110: 2678-2686.
15. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR, O'Grady HK, Davis CE: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993; 328: 1220-1225.
16. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
17. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of populationbased prospective studies. J Cardiovasc Risk 1996; 3: 213-219.
18. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D: ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS). Eur Heart J 2011;32:1769-1818.
19. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F: European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701.
20. Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, LaRosa JC, Larsen ML, Lindahl C, Olsson AG, Tikkanen MJ, Waters DD, Pedersen TR: Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009; 104: 459-463.
21. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM: Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of lowdensity lipoprotein cholesterol control. Am J Cardiol 2010; 106: 757-763.
22. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
23. Kohli P, Cannon CP: Triglycerides: How much credit do they deserve? Med Clin North Am 2012;96:39-55.
24. Thorin E: Vascular disease risk in patients with hypertriglyceridemia: endothelial progenitor cells, oxidative stress, accelerated senescence, and impaired vascular repair. Can J Cardiol 2011; 27: 538-540.
25. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen M-R, Tokgozoglu L, Tybjørg-Hansen A, Watts GF: Triglyceriderich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-1361.
26. Talayero BG, Sacks FM: The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011; 13: 544-552.
27. Greene DJ, Skeggs JW, Morton RE: Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 2001; 276: 4804-4811.
28. Ginsberg HN: Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 2001; 87: 1174-1180; A1174.
29. Ginsberg HN: New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106: 2137-2142.
30. Goldberg IJ, Eckel RH, McPherson R: Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011; 31: 1716-1725.
31. Nordestgaard BG, Varbo A: Triglycerides and cardiovascular disease. Lancet 2014;384:626-635.
32. Jacobs DR, Barrett-Connor E: Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol 1982; 116: 878-885.
33. Phillips AN, Smith GD: How independent are 'independent' effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991; 44: 1223-1231.
34. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18B-25B.
35. Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, Bishop L, Bonora E, Bunnag P, Chuang LM, Deerochanawong C, Goldenberg R, Harshfield B, Hernandez C, Herzlinger-Botein S, Itoh H, Jia W, Jiang YD, Kadowaki T, Laranjo N, Leiter L, Miwa T, Odawara M, Ohashi K, Ohno A, Pan C, Pan J, Pedro-Botet J, Reiner Z, Rotella CM, Simo R, Tanaka M, Tedeschi-Reiner E, Twum-Barima D, Zoppini G, Carey VJ: Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: A global case-control study in 13 countries. Circulation 2014;129:999-1008.